Eversept Partners, LP Aerie Pharmaceuticals Inc Transaction History

Eversept Partners, LP

$991 Million
Q4 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2023	BUY	$6.37 - $15.23 $1.63 Million - $3.9 Million	256,289 New	256,289 $3.88 Million
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $1.63 Million - $3.9 Million	256,289 New	256,289 $3.88 Million
Q2 2019 Aug 13, 2019	SELL	$28.97 - $48.21 $3.33 Million - $5.53 Million	-114,779 Closed	0 $0
Q1 2019 Nov 08, 2023	SELL	$36.32 - $49.25 $4.29 Million - $5.81 Million	-118,011 Reduced 50.69%	114,779 $5.45 Million
Q1 2019 May 14, 2019	SELL	$36.32 - $49.25 $4.29 Million - $5.81 Million	-118,011 Reduced 50.69%	114,779 $5.45 Million
Q4 2018 Nov 08, 2023	BUY	$33.0 - $60.04 $3.7 Million - $6.73 Million	112,079 Added 92.85%	232,790 $8.4 Million
Q4 2018 Feb 13, 2019	BUY	$33.0 - $60.04 $3.7 Million - $6.73 Million	112,079 Added 92.85%	232,790 $8.4 Million
Q3 2018 Nov 08, 2023	SELL	$56.15 - $73.9 $5.96 Million - $7.85 Million	-106,191 Reduced 46.8%	120,711 $7.43 Million
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $5.96 Million - $7.85 Million	-106,191 Reduced 46.8%	120,711 $7.43 Million
Q2 2018 Nov 08, 2023	BUY	$47.85 - $70.45 $771,533 - $1.14 Million	16,124 Added 7.65%	226,902 $15.3 Million
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $771,533 - $1.14 Million	16,124 Added 7.65%	226,902 $15.3 Million
Q1 2018 Nov 08, 2023	BUY	$51.15 - $61.0 $10.8 Million - $12.9 Million	210,778 New	210,778 $11.4 Billion
Q1 2018 May 14, 2018	SELL	$51.15 - $61.0 $1.57 Million - $1.87 Million	-30,702 Reduced 12.71%	210,778 $11.4 Million
Q4 2017 Nov 08, 2023	BUY	$50.85 - $65.1 $12.3 Million - $15.7 Million	241,480 New	241,480 $14.4 Billion
Q4 2017 Feb 12, 2018	BUY	$50.85 - $65.1 $12.3 Million - $15.7 Million	241,480	241,480 $14.4 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account